Adrenal gland cancer

Summary

Adrenal gland cancer (MONDO:0002817) is a cancer and 16 clinical trials. Top therapeutic interventions include floxuridine, mitotane, and nivolumab. A subtype of retroperitoneal cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 16

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	adrenal gland cancer
Mondo ID	MONDO:0002817
MeSH	D000310
DOID	DOID:3953
ICD-10-CM	C74
ICD-11	1766185236
NCIT	C9338
SNOMED CT	127021009
UMLS	C0750887
MedGen	152909
GARD	0005751
Anatomy (UBERON)	UBERON:0002369
Is cancer (heuristic)	yes

Also known as: adrenal cancer · adrenal gland cancer · adrenal neoplasm · cancer of adrenal gland · malignant adrenal gland neoplasm · malignant adrenal gland tumor · malignant adrenal gland tumour · malignant adrenal neoplasm · malignant adrenal tumor · malignant adrenal tumour · malignant neoplasm of adrenal gland · malignant neoplasm of the adrenal gland · malignant tumor of adrenal gland · malignant tumor of the adrenal gland · malignant tumour of adrenal gland · malignant tumour of the adrenal gland · tumor of the adrenal gland · tumour of the adrenal gland

Disease family

This is a subtype of retroperitoneal cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › retroperitoneal cancer › adrenal gland cancer

Related subtypes (3): retroperitoneal lymphoma, retroperitoneal sarcoma, retroperitoneum carcinoma

Subtypes (3): adrenal carcinoma, adrenal medulla cancer, malignant tumor of adrenal cortex

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 16.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	8
PHASE2	3
PHASE1	3
PHASE1/PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05286814	PHASE2	RECRUITING	PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
NCT06831175	PHASE2	RECRUITING	Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
NCT02001051	PHASE2	TERMINATED	Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism
NCT04785287	PHASE1/PHASE2	TERMINATED	Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
NCT04459273	PHASE1	ACTIVE_NOT_RECRUITING	Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
NCT07118176	PHASE1	RECRUITING	Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
NCT01898715	PHASE1	COMPLETED	Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma
NCT01086696	EARLY_PHASE1	TERMINATED	A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers
NCT01005654	Not specified	RECRUITING	Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
NCT06801340	Not specified	RECRUITING	Assessment of Metabolic Complications in Patients With Adrenal Tumors Through Radiological Images
NCT01185639	Not specified	COMPLETED	Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
NCT03083834	Not specified	UNKNOWN	Salivary Free Cortisol Response to Cosyntropin Stimulation Test in Mitotane Treated Patients
NCT03896958	Not specified	UNKNOWN	The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
NCT03986593	Not specified	TERMINATED	Cryoablation of Bone Metastases From Endocrine Tumors
NCT04028479	Not specified	COMPLETED	The Registry of Oncology Outcomes Associated With Testing and Treatment
NCT05888753	Not specified	COMPLETED	Textbook Outcome in Adrenal Neoplasms

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FLOXURIDINE	4	1
MITOTANE	4	1
NIVOLUMAB	4	1
FAPI-46 GA-68	2	2
NEVANIMIBE	2	2
CHEMBL1572655	0	1